Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol

Is hypertriglyceridemia a reliable indicator of cholesterol-depleted apoB particles?

(2023) Davide De Marco et al.   Journal of Clinical Lipidology

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

(2022) Emil Hagström et al.   CIRCULATION

The Lower the ApoB, the Better: Now, How Does ApoB Fit in the Upcoming Era of Targeted Therapeutics?

(2022) Mohamed B. Elshazly et al.   CIRCULATION

Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis

(2022) Anna Helgadottir et al.   European Journal of Preventive Cardiology

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

(2021) Camilla Ditlev Lindhardt Johannesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

(2021) Nicholas A. Marston et al.   JAMA Cardiology

The clinical utility of apoB versus LDL-C/non-HDL-C

(2020) Ciaran N. Kohli-Lynch et al.   CLINICA CHIMICA ACTA

Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary/Cross-Sector Collaboration

(2020) Christa M Cobbaert et al.   CLINICAL CHEMISTRY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Apolipoprotein B Particles and Cardiovascular Disease

(2019) Allan D. Sniderman et al.   JAMA Cardiology

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

(2019) Michel R. Langlois et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

(2018) Michel R. Langlois et al.   CLINICAL CHEMISTRY

A comparison of three apolipoprotein B methods and their associations with incident coronary heart disease risk over a 12-year follow-up period: The Multi-Ethnic Study of Atherosclerosis

(2018) Jing Cao et al.   Journal of Clinical Lipidology

Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization

(2018) Vincent Delatour et al.   CLINICAL CHEMISTRY

Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays

(2013) Marcelo Jose Andrade Oliveira et al.   CLINICA CHIMICA ACTA

Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices

(2013) T. G. Cole et al.   CLINICAL CHEMISTRY

Non-HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population

(2011) H. E. van Deventer et al.   CLINICAL CHEMISTRY

Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement

(2011) John H. Contois et al.   Journal of Clinical Lipidology

Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures

(2010) W. G. Miller et al.   CLINICAL CHEMISTRY

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

(2009) J. H. Contois et al.   CLINICAL CHEMISTRY

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

(2008) Allan D. Sniderman   Journal of Clinical Lipidology